ArticleOne health (Amsterdam, Netherlands)2025
Serological evaluation of Crimean-Congo Hemorrhagic fever in humans with High-Risk professional exposure and in residual sera collected in 2022-2023 across Corsica (France).
Article in One health (Amsterdam, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Widespread circulation of Crimean-Congo haemorrhagic fever virus in ticks, Corsica (France), 2024.One health (Amsterdam, Netherlands) · 2026Article
- First report of Crimean-Congo hemorrhagic fever virus exposure in human and livestock populations, Center Region, Cameroon.Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne pathogen known to cause severe viral hemorrhagic fever. Aim: We aimed to evaluate the potential circulation of CCHFV in Corsica through a serosurvey, including anonymized residual sera (RS) and high-risk individuals exposed to animals and/or tick bites due to occupational activities. Methods: This cross-sectional study involved two groups: anonymized RS from medical biology laboratories and sera from high-risk individuals (slaughterhouse workers, veterinary professionals, animal farmers, and rangers) collected across Corsica during 2022-2023. Antibodies targeting the CCHFV viral nucleoprotein were detected using a double-antigen ELISA. ELISA-positive samples underwent neutralizing antibody testing. Sociodemographic and epidemiological data were collected using a structured questionnaire in the high-risk group. Results: Total anti-CCHFV seropositivity was of 0.08 % ( Conclusions: This study provides initial evidence of human exposure to CCHFV in Corsica, with rates consistent with those observed in other Western European regions. Our results indicate a risk of CCHF among the Corsican population, particularly among farmers and slaughterhouse workers. Continuous surveillance and public education are essential to mitigate this risk, especially among these targeted groups and healthcare professionals, ensuring prompt diagnosis and prevention of potential outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.